Transitional CareTransition_psyNCT04333797
Psychiatry of Transition in a World in Transition
A study testing Risk and Protective Factors Assessment in people with Transitional Care and Mental Disorder in Adolescence, run by Queen Fabiola Children's University Hospital at 4 sites in Belgium.
Trial summary
This clinical study evaluates risk and protective factor to develop psychopathology in transitional age youth. 300 patients will be recruited at the age of 17 years old and assessed at baseline and 2 years later. Read more about this study
- Who is it for?
- Ages 17 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Transitional Care, Mental Disorder in Adolescence, Mental Health
- What is being tested?
- Risk and Protective Factors Assessment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 252 participants
- Where
- 4 sitesBelgium
- Study dates
- 10 Jun 2020to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- French-speaking and French-understanding
- Subjects who accepted to participated to the study (signature of informed consent/assent document from subjects and parents or legal holder of parental authority)
- Specific criteria for patients: inpatients and out-patients
- Specific criteria for control group: youth from general population or placed in residential centres
Who cannot join
- Impossibility to answer to the assessment tools
- Medium intellectual disability (homogenous IQ < 75)
- Presence of a grave somatic disease (cancer, cardiac failure, renal failure, central nervous system disorder), that is progressive or that affects the vital prognosis in the short term
- Active participation to another study
Trial locations and contacts
4 sites in 1 country.
Belgium4 sites
Brugmann University Hospital
Brussels, 1020
Hôpital Universitaire Des Enfants Reine Fabiola
Brussels, 1020
Service santé mentale à l'ULB
Brussels, 1050
Erasme University Hospital
Brussels, 1070
About this study
Official title: Multicentre Prospective Cohort Study Assessing Risk and Protective Factors to Develop Psychopathology in Transitional Age Youth
This clinical study evaluates risk and protective factor to develop psychopathology in transitional age youth. 300 patients will be recruited at the age of 17 years old and assessed at baseline and 2 years later.
Read the detailed description
Emerging adults are a particularly at-risk population in mental health. Transitional age youth have specific needs, not currently covered between child and adolescent mental health services (CAMHS) and adult mental health services (AMHS), mainly because of existing barriers. Movements from one to the other must be planned to achieve optimal patient care.
Our project aims to identify clinical dimensional characteristics contributing to the development of psychopathology during the transition period. Continuities, discontinuities and resilience factors will be explored. The final purpose is to develop a non-stigmatizing approach to reduce rejection from youths in psychopathological suffering and increase social inclusion.
The transversal and trans-diagnostic approach consists of a dimensional evaluation: 300 youth at the age of 17 will be included in a cohort of in-patients, out-patients and control group. Participants will be assessed at baseline and 2 years later. The primary outcome is based on Health of the Nation Outcome Scale for Children and Adolescents, measuring mental health care need, and WHO Quality of Life assessment.
The secondary outcomes include the assessment of dimensions representing risk or protective factors to develop psychopathology and evolution of mental health status during transition age. Baseline evaluation consists in internalizing/externalizing symptoms, impulsivity/compulsivity, emotion regulation, cognitive functioning, social and family functioning, developmental, medical and trauma history. At follow-up, mental health pathways and transition results will be described.
- Being tested
- Risk and Protective Factors Assessment
- Keywords
- Transitional age youth, CAMHS, AMHS, Dimensional approach, Child and Adolescent Psychiatry services, Adult Psychiatry services
- Medical subject headings
- Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Risk and Protective Factors AssessmentOther
Also called Transitional care from CAMHS to AMHS
First assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o.
| Study group | Role | What they receive |
|---|---|---|
| Transitional age youth | Other | Assessed group. Receives: Other: Risk and Protective Factors Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline self-rated mental health status (need for care) at 2 years
Measured at baseline (T0) and follow-up (T1) with the Health of the Nation Outcome Scale for Children and Adolescents (HoNOSCA).
Measured: Change from Baseline HoNOSCA before transition at 17 y.o. to after transition at 19 y.o.
Change from Baseline self-rated measure of quality of life at 2 years
Measured at baseline (T0) and follow-up (T1) with the Quality of life assessed by World Health Organisation Quality of Life Assessment (WHO-QoL-BREF)
Measured: Change from Baseline WHO-QoL before transition at 17 y.o. to after transition at 19 y.o
Secondary outcomes (18)
Self-rated measure of traumatic life events
Measured with Childhood Trauma Questionnaire (CTQ)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of family functioning
Measured with Family Assessment Device (FAD)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure to quantify the risk of developing psychiatric disorders
Measured with General Health Questionnaire (GHQ-12)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of internalising and externalising symptoms
Measured with Youth Self Report 11-18 (YSR)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of impulsivity and compulsivity
Measured with Barratt Impulsiveness Scale (BIS-11)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of depressivity
Measured with Beck Depression Inventory-II (BDI-II)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of suicidal risk
Measured with Beck Scale of Suicide Ideation (BSS)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of emotional regulation
Measured with Emotion Regulation Questionnaire for Children and Adolescents (ERQ-CA)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of interpersonal relationships social adaptation
Measured with Social Adaptation Self-evaluation Scale (SASS)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of cognitive insight
Measured with Beck Cognitive Insight Scale (BCIS)
Measured: Before transition at 17 y.o. (T0)
Cognitive assessment - IQ
Measured with Wechsler Adult Intelligence Scale (WAIS-IV)
Measured: Before transition at 17 y.o. (T0)
Executive functions assessment - alertness, divided attention, flexibility and working memory
Measured with Test of Attentional Performance (TAP)
Measured: Before transition at 17 y.o. (T0)
Executive functions assessment - cognitive inhibition
Measured with STROOP Task
Measured: Before transition at 17 y.o. (T0)
Executive functions assessment - planning task
Measured with Tower of London Test (TOL)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of executive functions
Measured with Behavior Rating Inventory of Executive Function - Self report (BRIEF-SR)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of transition readiness and appropriateness
Measured with Transition Readiness and Appropriateness Mesure (TRAM)
Measured: Before transition at 17 y.o. (T0)
Self-rated measure of therapeutic alliance
Measured with Helping Alliance Questionnaire (HAQ)
Measured: After transition at 19 y.o. (T1)
Self-rated measure of transition related outcomes
Measured with Transition Related Outcomes Mesure (TROM)
Measured: After transition at 19 y.o. (T1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2020
- Study start10 Jun 2020
- Primary completion31 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (57)Papers the sponsor has linked to this study.
- Other trials for Transitional CareStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 252 participants (actual)
Sponsor and investigators
- Lead sponsor
- Queen Fabiola Children's University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Erasme University Hospital, Brugmann University Hospital, Service santé mentale à l'ULB, Université Libre de Bruxelles, King Baudouin Foundation
- Responsible party
- Sponsor
- Investigators
- Véronique Delvenne, MD, PhD, Principal investigator, Queen Fabiola Children's University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04333797
- Sponsor's protocol ID
- P2020/PSY/Transition_psy
- Acronym
- Transition_psy
- Status last verified
- Jun 2020
- First submitted
- 27 Mar 2020
- Last updated
- 7 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Caspi A, Moffitt TE. All for One and One for All: Mental Disorders in One Dimension. Am J Psychiatry. 2018 Sep 1;175(9):831-844. doi: 10.1176/appi.ajp.2018.17121383. Epub 2018 Apr 6.
PubMed 29621902Tuomainen H, Schulze U, Warwick J, Paul M, Dieleman GC, Franic T, Madan J, Maras A, McNicholas F, Purper-Ouakil D, Santosh P, Signorini G, Street C, Tremmery S, Verhulst FC, Wolke D, Singh SP; MILESTONE consortium. Managing the link and strengthening transition from child to adult mental health Care in Europe (MILESTONE): background, rationale and methodology. BMC Psychiatry. 2018 Jun 4;18(1):167. doi: 10.1186/s12888-018-1758-z.
PubMed 29866202Singh SP, Paul M, Ford T, Kramer T, Weaver T. Transitions of care from Child and Adolescent Mental Health Services to Adult Mental Health Services (TRACK Study): a study of protocols in Greater London. BMC Health Serv Res. 2008 Jun 23;8:135. doi: 10.1186/1472-6963-8-135.
PubMed 18573214Hovish K, Weaver T, Islam Z, Paul M, Singh SP. Transition experiences of mental health service users, parents, and professionals in the United Kingdom: a qualitative study. Psychiatr Rehabil J. 2012 Winter;35(3):251-7. doi: 10.2975/35.3.2012.251.257.
PubMed 22246124Leebens PK, Williamson ED. Developmental Psychopathology: Risk and Resilience in the Transition to Young Adulthood. Child Adolesc Psychiatr Clin N Am. 2017 Apr;26(2):143-156. doi: 10.1016/j.chc.2016.12.001.
PubMed 28314447Singh SP, Tuomainen H. Transition from child to adult mental health services: needs, barriers, experiences and new models of care. World Psychiatry. 2015 Oct;14(3):358-61. doi: 10.1002/wps.20266. No abstract available.
PubMed 26407794Paul M, Street C, Wheeler N, Singh SP. Transition to adult services for young people with mental health needs: A systematic review. Clin Child Psychol Psychiatry. 2015 Jul;20(3):436-57. doi: 10.1177/1359104514526603. Epub 2014 Apr 7.
PubMed 24711585McGorry P, Bates T, Birchwood M. Designing youth mental health services for the 21st century: examples from Australia, Ireland and the UK. Br J Psychiatry Suppl. 2013 Jan;54:s30-5. doi: 10.1192/bjp.bp.112.119214.
PubMed 23288499Gore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C, Sawyer SM, Mathers CD. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet. 2011 Jun 18;377(9783):2093-102. doi: 10.1016/S0140-6736(11)60512-6. Epub 2011 Jun 7.
PubMed 21652063Kotov R, Ruggero CJ, Krueger RF, Watson D, Yuan Q, Zimmerman M. New dimensions in the quantitative classification of mental illness. Arch Gen Psychiatry. 2011 Oct;68(10):1003-11. doi: 10.1001/archgenpsychiatry.2011.107.
PubMed 21969458Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry. 2003 Jul;60(7):709-17. doi: 10.1001/archpsyc.60.7.709.
PubMed 12860775Jones PB. Adult mental health disorders and their age at onset. Br J Psychiatry Suppl. 2013 Jan;54:s5-10. doi: 10.1192/bjp.bp.112.119164.
PubMed 23288502Snyder HR, Gulley LD, Bijttebier P, Hartman CA, Oldehinkel AJ, Mezulis A, Young JF, Hankin BL. Adolescent emotionality and effortful control: Core latent constructs and links to psychopathology and functioning. J Pers Soc Psychol. 2015 Dec;109(6):1132-49. doi: 10.1037/pspp0000047. Epub 2015 May 25.
PubMed 26011660Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602. doi: 10.1001/archpsyc.62.6.593.
PubMed 15939837Copeland WE, Wolke D, Shanahan L, Costello EJ. Adult Functional Outcomes of Common Childhood Psychiatric Problems: A Prospective, Longitudinal Study. JAMA Psychiatry. 2015 Sep;72(9):892-9. doi: 10.1001/jamapsychiatry.2015.0730.
PubMed 26176785
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicentre Prospective Cohort Study Assessing Risk and Protective Factors to Develop Psychopathology in Transitional Age Youth
- ClinicalTrials.gov ID
- NCT04333797
- Acronym / sponsor ID
- Transition_psy / P2020/PSY/Transition_psy
- Keywords
- Transitional age youth, CAMHS, AMHS, Dimensional approach, Child and Adolescent Psychiatry services, Adult Psychiatry services
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 252 participants (actual)
- Lead sponsor
- Queen Fabiola Children's University HospitalUniversity, hospital or other
- Collaborators
- Erasme University Hospital, Brugmann University Hospital, Service santé mentale à l'ULB, Université Libre de Bruxelles, King Baudouin Foundation
- Study start
- 10 Jun 2020 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 3 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical study evaluates risk and protective factor to develop psychopathology in transitional age youth. 300 patients will be recruited at the age of 17 years old and assessed at baseline and 2 years later.
Detailed description
Emerging adults are a particularly at-risk population in mental health. Transitional age youth have specific needs, not currently covered between child and adolescent mental health services (CAMHS) and adult mental health services (AMHS), mainly because of existing barriers. Movements from one to the other must be planned to achieve optimal patient care.
Our project aims to identify clinical dimensional characteristics contributing to the development of psychopathology during the transition period. Continuities, discontinuities and resilience factors will be explored. The final purpose is to develop a non-stigmatizing approach to reduce rejection from youths in psychopathological suffering and increase social inclusion.
The transversal and trans-diagnostic approach consists of a dimensional evaluation: 300 youth at the age of 17 will be included in a cohort of in-patients, out-patients and control group. Participants will be assessed at baseline and 2 years later. The primary outcome is based on Health of the Nation Outcome Scale for Children and Adolescents, measuring mental health care need, and WHO Quality of Life assessment.
The secondary outcomes include the assessment of dimensions representing risk or protective factors to develop psychopathology and evolution of mental health status during transition age. Baseline evaluation consists in internalizing/externalizing symptoms, impulsivity/compulsivity, emotion regulation, cognitive functioning, social and family functioning, developmental, medical and trauma history. At follow-up, mental health pathways and transition results will be described.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Transitional age youth | Other | Other: Risk and Protective Factors AssessmentAssessed group. |
Who may qualify
- Ages
- 17 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- French-speaking and French-understanding
- Subjects who accepted to participated to the study (signature of informed consent/assent document from subjects and parents or legal holder of parental authority)
- Specific criteria for patients: inpatients and out-patients
- Specific criteria for control group: youth from general population or placed in residential centres
Key exclusion criteria (4 listed)
- Impossibility to answer to the assessment tools
- Medium intellectual disability (homogenous IQ < 75)
- Presence of a grave somatic disease (cancer, cardiac failure, renal failure, central nervous system disorder), that is progressive or that affects the vital prognosis in the short term
- Active participation to another study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Risk and Protective Factors AssessmentAlso: Transitional care from CAMHS to AMHSFirst assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o. | Other | Transitional age youth |
Primary outcome
Change from Baseline self-rated mental health status (need for care) at 2 years
Time frame: Change from Baseline HoNOSCA before transition at 17 y.o. to after transition at 19 y.o.
Measured at baseline (T0) and follow-up (T1) with the Health of the Nation Outcome Scale for Children and Adolescents (HoNOSCA).
Change from Baseline self-rated measure of quality of life at 2 years
Time frame: Change from Baseline WHO-QoL before transition at 17 y.o. to after transition at 19 y.o
Measured at baseline (T0) and follow-up (T1) with the Quality of life assessed by World Health Organisation Quality of Life Assessment (WHO-QoL-BREF)
18 secondary outcomes
Self-rated measure of traumatic life events
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of family functioning
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure to quantify the risk of developing psychiatric disorders
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of internalising and externalising symptoms
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of impulsivity and compulsivity
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of depressivity
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of suicidal risk
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of emotional regulation
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of interpersonal relationships social adaptation
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of cognitive insight
Time frame: Before transition at 17 y.o. (T0)
Cognitive assessment - IQ
Time frame: Before transition at 17 y.o. (T0)
Executive functions assessment - alertness, divided attention, flexibility and working memory
Time frame: Before transition at 17 y.o. (T0)
Executive functions assessment - cognitive inhibition
Time frame: Before transition at 17 y.o. (T0)
Executive functions assessment - planning task
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of executive functions
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of transition readiness and appropriateness
Time frame: Before transition at 17 y.o. (T0)
Self-rated measure of therapeutic alliance
Time frame: After transition at 19 y.o. (T1)
Self-rated measure of transition related outcomes
Time frame: After transition at 19 y.o. (T1)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2026.
- Background: PubMed 29621902Caspi A, Moffitt TE. All for One and One for All: Mental Disorders in One Dimension. Am J Psychiatry. 2018 Sep 1;175(9):831-844. doi: 10.1176/appi.ajp.2018.17121383. Epub 2018 Apr 6.
- Background: PubMed 29866202Tuomainen H, Schulze U, Warwick J, Paul M, Dieleman GC, Franic T, Madan J, Maras A, McNicholas F, Purper-Ouakil D, Santosh P, Signorini G, Street C, Tremmery S, Verhulst FC, Wolke D, Singh SP; MILESTONE consortium. Managing the link and strengthening transition from child to adult mental health Care in Europe (MILESTONE): background, rationale and methodology. BMC Psychiatry. 2018 Jun 4;18(1):167. doi: 10.1186/s12888-018-1758-z.
- Background: PubMed 18573214Singh SP, Paul M, Ford T, Kramer T, Weaver T. Transitions of care from Child and Adolescent Mental Health Services to Adult Mental Health Services (TRACK Study): a study of protocols in Greater London. BMC Health Serv Res. 2008 Jun 23;8:135. doi: 10.1186/1472-6963-8-135.
- Background: PubMed 22246124Hovish K, Weaver T, Islam Z, Paul M, Singh SP. Transition experiences of mental health service users, parents, and professionals in the United Kingdom: a qualitative study. Psychiatr Rehabil J. 2012 Winter;35(3):251-7. doi: 10.2975/35.3.2012.251.257.
- Background: PubMed 28314447Leebens PK, Williamson ED. Developmental Psychopathology: Risk and Resilience in the Transition to Young Adulthood. Child Adolesc Psychiatr Clin N Am. 2017 Apr;26(2):143-156. doi: 10.1016/j.chc.2016.12.001.
- Background: PubMed 26407794Singh SP, Tuomainen H. Transition from child to adult mental health services: needs, barriers, experiences and new models of care. World Psychiatry. 2015 Oct;14(3):358-61. doi: 10.1002/wps.20266. No abstract available.
- Background: PubMed 24711585Paul M, Street C, Wheeler N, Singh SP. Transition to adult services for young people with mental health needs: A systematic review. Clin Child Psychol Psychiatry. 2015 Jul;20(3):436-57. doi: 10.1177/1359104514526603. Epub 2014 Apr 7.
- Background: PubMed 23288499McGorry P, Bates T, Birchwood M. Designing youth mental health services for the 21st century: examples from Australia, Ireland and the UK. Br J Psychiatry Suppl. 2013 Jan;54:s30-5. doi: 10.1192/bjp.bp.112.119214.
- Background: PubMed 21652063Gore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C, Sawyer SM, Mathers CD. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet. 2011 Jun 18;377(9783):2093-102. doi: 10.1016/S0140-6736(11)60512-6. Epub 2011 Jun 7.
- Background: PubMed 21969458Kotov R, Ruggero CJ, Krueger RF, Watson D, Yuan Q, Zimmerman M. New dimensions in the quantitative classification of mental illness. Arch Gen Psychiatry. 2011 Oct;68(10):1003-11. doi: 10.1001/archgenpsychiatry.2011.107.
- Background: PubMed 12860775Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry. 2003 Jul;60(7):709-17. doi: 10.1001/archpsyc.60.7.709.
- Background: PubMed 23288502Jones PB. Adult mental health disorders and their age at onset. Br J Psychiatry Suppl. 2013 Jan;54:s5-10. doi: 10.1192/bjp.bp.112.119164.
- Individual participant dataSharing planned: No
Related trials for Transitional Care
Recruiting
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
Liver Diseases
RecruitingPhase 3
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Enrolling by invitation
BETTER (Brain Injury Education, Training, and Therapy to Enhance Recovery)
Traumatic Brain Injury
Active, not recruitingPhase 3
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Active, not recruitingPhase 2
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Véronique Delvenne, MD, PhD principal investigator
Queen Fabiola Children's University Hospital
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Risk and Protective Factors Assessment in people with Transitional Care and Mental Disorder in Adolescence, run by Queen Fabiola Children's University Hospital at 4 sites in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline self-rated mental health status (need for care) at 2 years (time frame: Change from Baseline HoNOSCA before transition at 17 y.o. to after transition at 19 y.o.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04333797, which also lists 57 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.